** Shares of LTR Pharma rise 7.9% to A$0.755
** The biopharmaceutical firm rose as much as 17.9% earlier in the day, their biggest intraday gain since early November
** Co enters an agreement with Australian pharmaceutical wholesaler Symbion for nation-wide distribution for SPONTAN
** SPONTAN is LTR Pharma's lead product for treatment of erectile dysfunction
** About 1.2 mln shares change hands, compared with 30-day average trading volume of 669,941 shares
** Stock down 13.6% YTD, as of last close
(Reporting by John Biju in Bengaluru)
((John.Biju@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。